[Form 4] AbbVie Inc. Insider Trading Activity

Rhea-AI Filing Summary

Susan E. Quaggin, an AbbVie Inc. (ABBV) director, had 67 stock equivalent units credited to her account on 09/30/2025 at a unit value of $231.54. The filing shows these units are held in a grantor trust and are paid in cash generally at age 65 or upon retirement from the board; they earn returns as if invested in AbbVie stock. The report indicates a post-transaction beneficial ownership balance of 634 shares (including units acquired through a dividend reinvestment feature).

Positive

• 67 stock equivalent units credited to director aligns compensation with company performance
• Units are held in a grantor trust that track AbbVie stock returns, preserving economic alignment
• Post-transaction beneficial ownership reported as 634 shares, including dividend reinvestment

Negative

• None.

Insights

Corporate Governance Expert

Director compensation recorded as stock-equivalent units; modest ownership change.

The Form 4 shows a non-cash credit of 67 stock equivalent units to Susan E. Quaggin on 09/30/2025 at a reported value of $231.54 per unit. These units are part of a grantor trust that pays in cash at age 65 or upon board retirement and track AbbVie stock returns.

This transaction increases reported beneficial ownership to 634 shares when including a dividend reinvestment feature. The filing documents routine director compensation treatment rather than an open-market purchase or sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Quaggin Susan E

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Equivalent Units	$231.54	09/30/2025		A		67		(1)	(1)	Common Stock	67	$231.54	634(2)	D

Explanation of Responses:

1. Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

	/s/ T.O. Odutayo, Attorney-in-Fact for Susan E. Quaggin	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did AbbVie director Susan E. Quaggin report on Form 4 (ABBV)?

The Form 4 reports crediting of 67 stock equivalent units on 09/30/2025 at $231.54 per unit, increasing reported beneficial ownership to 634 shares.

How are the credited stock equivalent units paid to the director?

The units are held in a grantor trust and are paid in cash generally at age 65 or upon retirement from the board.

Do the stock equivalent units earn returns like AbbVie stock?

Yes. The filing states the stock equivalent units "earn the same return as if the fees were invested in AbbVie stock."

Does the reported beneficial ownership include dividend reinvestment?

Yes. The filing explains the balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

When was the Form 4 signed and filed for this transaction?

The Form 4 indicates the signature by attorney-in-fact on 10/02/2025 and lists the transaction date as 09/30/2025.